---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-041796"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2024-10-21T23:59:59+00:00"
generated_at: "2026-05-30T12:19:03.285222+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Daré Bioscience secures $15M common stock purchase facility with Lincoln Park Capital

## Summary
- Entered $15M common stock purchase agreement with Lincoln Park Capital Fund, LLC.
- Daré has sole discretion to sell up to $15M shares over 24 months; LPC obligated to buy at market-based prices.
- Proceeds intended to help fund Phase 3 program for Sildenafil Cream, 3.6% (estimated $15M direct costs).
- Issued 137,614 commitment shares to LPC; no warrants issued, no short selling permitted.
- Daré may terminate agreement at any time with no cost or penalty.

## SEC filing metadata
- accession: 0001493152-24-041796
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2024-10-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000149315224041796/0001493152-24-041796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000149315224041796/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-041796
- JSON: https://secwatch.observer/filing/0001493152-24-041796.json
- Plain text: https://secwatch.observer/filing/0001493152-24-041796.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.